Dose-escalation study
Showing 1 - 25 of >10,000
Metastatic Castration-resistant Prostate Cancer Trial (HP518 - Dose Escalation, HP518 -Dose Expansion)
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer
- HP518 - Dose Escalation
- HP518 -Dose Expansion
- (no location specified)
Dec 1, 2023
Glioblastoma Trial (Dose escalation of radiation dose beyond the therapeutic standard)
Not yet recruiting
- Glioblastoma
- Dose escalation of radiation dose beyond the therapeutic standard
- (no location specified)
May 13, 2023
Head and Neck Squamous Cell Carcinoma Trial in Delhi (DE-HyART, Standard Arm, Cisplatin injection)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- DE-HyART
- +3 more
-
Delhi, IndiaRajiv Gandhi Cancer Institute and Research Centre
Oct 20, 2023
Colorectal Cancer, Esophagus Cancer, Appendix Cancer Trial (FOX dose-escalation algorithm)
Not yet recruiting
- Colorectal Cancer
- +4 more
- FOX dose-escalation algorithm
- (no location specified)
Mar 24, 2023
Idiopathic Pulmonary Fibrosis Trial in Stanford (Artesunate Oral Product)
Not yet recruiting
- Idiopathic Pulmonary Fibrosis
- Artesunate Oral Product
-
Stanford, CaliforniaStanford University
Aug 4, 2023
Corneal Epithelial Degeneration Trial in Cypress (TTHX1114(NM141) Ophthalmic Solution)
Recruiting
- Corneal Epithelial Degeneration
- TTHX1114(NM141) Ophthalmic Solution
-
Cypress, CaliforniaTrefoil Clinical Site #132
Mar 3, 2023
Facet Joints; Degeneration, Back Pain, Facet Joint Pain Trial (Alocyte low dose, Alocyte medium dose, Alocyte high dose)
Not yet recruiting
- Facet Joints; Degeneration
- +2 more
- Alocyte low dose
- +2 more
- (no location specified)
Jun 8, 2023
Prostate Adenocarcinoma Trial in Madrid (Prostate SBRT (stereotactic body radiation therapy) with focal boost)
Not yet recruiting
- Prostate Adenocarcinoma
- Prostate SBRT (stereotactic body radiation therapy) with focal boost
-
Madrid, SpainLa Princesa University Hospital, Health Research Institute, Madr
Jun 16, 2023
LGMD2C Trial (ATA-200)
Not yet recruiting
- LGMD2C
- ATA-200
- (no location specified)
Aug 1, 2023
Sinusoidal Obstruction Syndrome, Veno-occlusive Disease Trial (Defibrotide)
Not yet recruiting
- Sinusoidal Obstruction Syndrome
- Veno-occlusive Disease
- (no location specified)
Aug 4, 2023
Liver Cancer, Hepatocellular Carcinoma Trial (Regorafenib Oral Product)
Not yet recruiting
- Liver Cancer
- Hepatocellular Carcinoma
- Regorafenib Oral Product
- (no location specified)
Nov 17, 2022
Cachexia Trial (AV-380)
Not yet recruiting
- Cachexia
- AV-380
- (no location specified)
May 9, 2023
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms Trial in Wahroonga, Tauranga (RT-310)
Not yet recruiting
- BPH (Benign Prostatic Hyperplasia)
- Lower Urinary Tract Symptoms
- RT-310
-
Wahroonga, New South Wales, Australia
- +1 more
Nov 13, 2023
Paroxysmal Nocturnal Hemoglobinuria Trial in Bloemfontein, Cape Town, Pretoria (BCX10013)
Recruiting
- Paroxysmal Nocturnal Hemoglobinuria
-
Bloemfontein, South Africa
- +2 more
Oct 20, 2023
Solid Tumor, Adult Trial in Belgium, France (DT-9081 - dose escalation, DT-9081 - expansion)
Recruiting
- Solid Tumor, Adult
- DT-9081 - dose escalation
- DT-9081 - expansion
-
Anderlecht, Belgium
- +3 more
Jan 5, 2023
Pain, Postoperative Trial in Seongnam-si (GB-6002, Placebo, Naropin injection)
Recruiting
- Pain, Postoperative
- GB-6002
- +2 more
-
Seongnam-si, Korea, Republic ofSeoul National University Bundang Hospital
Oct 17, 2023
Cough Trial in Jinan (HS-10383, HS-10383 Placebo)
Recruiting
- Cough
- HS-10383
- HS-10383 Placebo
-
Jinan, Shandong, ChinaShandong provincial qianfoshan hospital
Oct 19, 2023
HPV Infection, HPV-Related Cervical Carcinoma Trial (FluBHPVE6E7, Placebo)
Not yet recruiting
- HPV Infection
- HPV-Related Cervical Carcinoma
- FluBHPVE6E7
- Placebo
- (no location specified)
Apr 24, 2023
Ovarian Cancer Trial in Lexington (Lapatinib and Paclitaxel)
Recruiting
- Ovarian Cancer
- Lapatinib and Paclitaxel
-
Lexington, KentuckyMarkey Cancer Center
Dec 2, 2022
Ovarian Cancer Trial in Lexington (Artemisia annua 450mg, Artemisia annua 900mg, Artemisia annua 1350mg)
Recruiting
- Ovarian Cancer
- Artemisia annua 450mg
- +4 more
-
Lexington, KentuckyUniversity of Kentucky
Jan 4, 2023